Novo CEO Willing To Testify On Weight-Loss Drugs After Sanders Threatens To Subpoena Novo President

The Senate health committee will vote next week on whether to subpoena Novo Nordisk President Doug Langa to testify on why the company charges high U.S. prices for its type-2 diabetes and obesity drugs, Ozempic and Wegovy, an escalation of Chair Bernie Sanders’ (I-VT) efforts to demand lower prices for the drugs. A Novo Nordisk spokesperson tells Inside Health Policy that its global CEO Lars Fruergaard Jørgensen, who is better versed in reference pricing, is willing to testify, and...